单中心11例肝内胆管细胞癌肝移植疗效分析

Objective To evaluate the effect of liver transplantation(LT)on the prognosis in patients with intrahepatic cholangiocarcinoma(ICC).Methods A retrospective analysis was performed on 11 consecutive patients with ICC who underwent LT between October 2003 and November 2008 at our institution.The overall and disease-free survival rates were calculated by the Kaplan-Mayer method.Results The median survival time Was 9.0 months(2.5-53 months).The 1-,2-,3-and 4-year disease-free survival rate and overall survival rate of all the patients were 51.9%、51.9%、51.9%、51.9%and 50.5%、50.5%、50.5%、50.5%,respectively.The perioperative mortality and the recurrence rate were 0 and 43.5%,respectively.The survival rate and disease-free survival time of patients with recurrence were 2.5-10 months(mean 7.5 months)and 1-8 months(mean 3.8 months).Conclusions The prognosis of LT for ICC is rather poor.ICC patients with lymph node metastasis.vascular or bile duct invasion is contraindicated for LT.     

5-脂氧合酶在缺血脑组织和脑脊髓损伤及阿尔茨海默病中的作用

正5-脂氧合酶(5-lipoxygenase,5-LOX)是花生四烯酸生成白三烯类介质(leukotrienes,LTs)的限速酶,其在正常中枢神经系统中表达较少,病理状态时表达增多,甚至过度表达。5-LOX参与了脑缺血、脑损伤、脊髓损伤和阿尔茨海默病(Alzheimer's disease,AD)等疾病的发生和发展[1-2]。笔者对以5-LOX为靶点预防或干预该类疾病的可行性综述如下。1概述静息状态下,5-LOX通常位于细胞质或细胞核内,当机体受内外各种刺激作用时,5-LOX则转移至     

肝动脉-腹主动脉架桥重建移植肝肝动脉74例报告

目的探讨原位肝移植术中采用肝动脉-腹主动脉架桥重建移植肝肝动脉的疗效。方法回顾分析2003年10月至2009年8月在中山大学附属第三医院肝移植中心行肝动脉-腹主动脉架桥重建移植肝肝动脉的74例患者的临床资料。全部患者采用供肝动脉通过供者髂动脉间置架桥与受者腹主动脉(肾动脉下方腹主动脉)行端侧吻合。总结手术治疗方法和术后并发症发生情况。所有患者均签署知情同意书,符合医学伦理学规定。结果 74例采用肝动脉-腹主动脉架桥重建肝动脉的患者中,68例治愈,6例术后早期死亡,治愈率为92%。术后急性排斥反应的发生率为18%(13/74),胆道并发症发生率为11%(8/74),肝动脉并发症发生率为14%(10/74),其中5例为架桥动脉血栓形成,5例为肝动脉(含架桥动脉)狭窄,行动脉支架置入溶栓术或动脉支架置入术,除1例上述治疗无效后行再次肝移植外,其余9例血管恢复通畅。结论肝移植术中若无法行供、受者肝动脉端端吻合术重建肝动脉,间置髂动脉的肝动脉-腹主动脉架桥术是一种安全可靠的肝动脉重建方法。     

西罗莫司对人肝癌裸鼠肝脏移植瘤生长的影响

Objective To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice. Methods HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynuclcotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay. Results The tumor weight was (352±38) mg, (683±53) mg and (675±45) mg in SRL, FKS06 and control group respectively. The tumor weight was significantly decreased in SRL group (P < 0.0 I), and there was no difference between FKS06 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P < 0.05), and it was not significantly different between FK506 group and control group (P > 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P < 0.01). Conclusion SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis.     

ԭλ����ֲ���󵨵���խ�Ľ�������

目的 探讨原位肝移植(OLT)术后胆道狭窄(BS)的介入治疗方法和疗效。方法 1993年1月至2003年5月，应用经皮肝穿刺胆道造影(PTC)、经十二指肠镜逆行胆道造影(ERC)或经T管窦道胆道球囊扩张术、内支架术或引流术治疗7例OLT术后BS。结果 7例中2例经PTC胆道介入治疗3次，2次成功；5人经ERC胆道介入治疗13次，均成功；1例经T管窦道胆道引流3次，均成功。6例治愈，治愈率达85．7％。1例长期携带肝内胆管引流管，术后13个月死于肝功能衰竭。结论 经PTC、ERC或T管窦道胆道球囊扩张术、内支架术或引流术是OLT术后BS的有效介入治疗方法。     

����ֲΧ�������ž���Ѫ˨�Ĵ���

目的　探讨肝移植围手术期门静脉血栓的处理。方法　回顾性分析 2 0 0 3年 10月至 2 0 0 4年 6月 14 0例原位肝移植病人的临床资料。结果　通过彩色多普勒、螺旋CT加三维血管成像和间接门脉造影共确诊肝移植术前门静脉血栓 5例。其中螺旋CT加三维血管成像 (CTA)对门静脉血栓的诊断特异性为 10 0 % ,彩色多普勒的诊断特异性为 80 % ,间接门脉造影的诊断特异性为 2 0 %。肝移植术中采用门静脉血栓切除术治疗成功率为10 0 %。结论　肝移植术中门静脉血栓切除术是治疗门静脉血栓的有效方法。CTA检查能准确判断门静脉血栓的程度。肝移植术后预防性抗凝能有效预防门静脉血栓复发。     

预缺血对肝脏缺血再灌注损伤的保护作用

已有较多的实验证明,预缺血处理对多种缺血再灌注器官有保护作用.本文综述了预缺血对缺血再灌注肝脏的保护作用及其机理.     

重组人硫氧化还原蛋白对原代培养肝细胞的影响

目的探讨重组人硫氧化还原蛋白(rhTrx)对原代培养肝细胞生存生长的影响。方法逆转录聚合酶链反应法扩增出hTrx cDNA,并在原核表达系统中表达。IgM还原实验和胰岛素还原实验测定rhTrx的生物学活性。3H胸腺嘧啶核苷(TdR)掺入试验和细胞乳酸脱氢酶(LDH)释放试验检测rhTrx对SD大鼠原代培养肝细胞生存生长的影响。结果克隆出hTrx开放阅读框cDNA并获得高效表达,可溶性目的蛋白回收率为23．20％,蛋白纯度为96．30％。IgM还原和胰岛素还原实验均显示制备的rhTrx具有较好的生物学活性(t=7．5860,P<0．01)。加入rhTrx培养的肝细胞生长旺盛,并维持了良好的细胞形态。rhTrx可促进原代培养肝细胞的DNA合成,并以剂量依赖方式明显抑制乙醇造成的肝细胞损害。结论制备出具有生物学活性的rhTrx,hTrx对原代培养肝细胞的生存具有促进作用。     

Zwint高表达对肝癌细胞增殖和肝癌肝移植预后的影响

目的探讨Zw10结合因子(Zwint)在原发性肝癌(肝癌)中的表达情况及其对肝癌肝移植预后的影响。方法收集50例肝癌肝移植受体的肝癌组织、癌旁组织及临床资料。采用实时荧光定量聚合酶链反应(PCR)、蛋白免疫印迹(Western Blot)法和免疫组织化学(免疫组化)法,分别比较20例肝癌肝移植受体的20对肝癌组织及癌旁组织中Zwint信使核糖核酸(m RNA)表达情况和Zwint蛋白的表达水平;选取两个成功干扰Zwint表达的肝癌细胞系Hep G-2(si-Zwint-1组和si-Zwint-2组),以空白对照作为si-NC组,采用细胞计数试剂盒(CCK)-8实验、平板克隆实验和细胞周期实验,比较各组细胞的增殖能力和细胞周期;采用Western Blot法和免疫组化法,分析肝癌组织和肝癌细胞中Zwint与细胞周期蛋白D1(cyclin D1)表达的一致性;以Zwint蛋白表达水平的中位数为分割点,将入组病例分高表达组(22例)和低表达组(28例),分析Zwint蛋白表达水平与肝癌肝移植受体临床特征、总体存活率及无复发存活率的关系。结果实时荧光定量PCR结果提示肝癌组织中Zwint m RNA表达水平高于癌旁组织(P=0.03)。Western Blot及免疫组化结果均提示肝癌组织中Zwint蛋白的表达水平高于癌旁组织(均为P0.05)。干扰肝癌细胞系Hep G-2的Zwint基因后,CCK-8及平板克隆实验显示细胞增殖能力明显减弱(均为P0.01),细胞周期阻滞于G1期(均为P0.05)。Zwint蛋白表达水平与肿瘤直径和肿瘤、淋巴、转移(TNM)分期密切相关(均为P0.05)。Zwint高表达组肝癌肝移植受体的总体存活率低于低表达组(P=0.02)。结论 Zwint高表达于肝癌组织,其通过调节细胞周期促进肝癌细胞增殖,且Zwint表达水平与肝癌肝移植后预后呈负相关。